Superluminal Medicines develops small-molecule therapeutics using generative biology, chemistry, machine learning, and proprietary data infrastructure. Its Hyperloop platform integrates structure-based drug discovery, computational approaches, and experimental research to identify and validate drug candidates. The company focuses on GPCR-targeted treatments, particularly for cardiometabolic diseases, obesity, and rare genetic conditions.